BioSpace News Archive

The BioForest region is growing up. With a focus on cell and gene therapy, a wealth of talent and proximity to high tech, it is quickly becoming one of biotech’s most exciting hotbeds.

Recently, Sanyou Biopharmaceuticals Co., Ltd. and Shanghai KangaBio Co., Ltd. have reached an antibody drug licensing agreement, regarding a proprietary monoclonal antibody drug developed by Sanyou, which grants KangaBio an exclusive license to exploit the antibody for research, development, manufacturing and commercialization of immunotherapy products.

Detailed results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA® significantly reduced the composite of cardiovascular death or worsening heart failure in patients with HF and mildly reduced or preserved ejection fraction, compared to placebo.